Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

4

Revenue 2017

Herceptin

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Herceptin was produced by Roche.

Roche gets EU approval for fixed-dose Herceptin/Perjeta combination

Roche gets EU approval for fixed-dose Herceptin/Perjeta combination

The European Commission has approved a fixed dose combination of Roche’s antibody blockbusters Herceptin and Perjeta under the new brand name Phesgo. ... In Roche’s half-year report for 2020, sales of Herceptin had dropped by 28%, reflecting the

Roche cites COVID-19 and biosimilars in Q2 decline

Roche cites COVID-19 and biosimilars in Q2 decline Much of that decline can be attributed to increasing biosimilar competition to three of Roche’s key cancer therapies – Herceptin (trastuzumab), Avastin (bevacizumab) and Rituxan (rituximab).

EMA fast-tracks review of AZ/Daiichi Sankyo’s HER2 drug

EMA fast-tracks review of AZ/Daiichi Sankyo’s HER2 drug The drug presents a new challenge to Roche’s dominant position in the HER2-positive breast cancer market, which includes a trio of targeted treatments – Herceptin (trastuzumab), Perjeta (pertuzumab) and Kadcyla ... The FDA approval and EMA

Cortellis Drugs to Watch in 2020 report

Cortellis Drugs to Watch in 2020 report It has entered into a market dominated by Herceptin and other HER2-targeted therapies such as Perjeta and Tykerb.

Roche’s Herceptin/Perjeta fixed-dose combo filed with FDA

Roche’s Herceptin/Perjeta fixed-dose combo filed with FDA Last year, sales of Herceptin were flat overall at around $7bn, but fell 16% in Europe and Japan as biosimilars started to gather momentum. ... Perjeta has been growing strongly – rising a third to $2.8bn last year – thanks to data showing it

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
11 London

11 London is a strategic and creative agency working in the fields of health and humanity – complex areas, but...

Latest intelligence

Emre Vural
Sourcing R&D innovation: why pharma companies need to evolve their business models
Recent years have seen a significant shift in drug development to specialty areas...
2020 - a year to remember or forget?
2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...
Gilead Headquarters
The search for effective drug treatments for COVID-19
PME talks to Julian Cole, Senior Director, Medical Affairs at Gilead Sciences...

Infographics